SYS6051 / CSPC Pharma - LARVOL DELTA

A Study of SYS6051 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=114 | Not yet recruiting | Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd.

New P1 trial • Oncology • Solid Tumor

CSPC Pharmaceutical Group has received U.S. Food and Drug Administration approval for an Investigational New Drug application covering SYS6051, an antibody-drug conjugate targeting tissue factor on tumor cells, enabling clinical trials in the U.S. SYS6051 also secured clearance from China’s National Medical Products Administration in April 2026 for clinical trials in advanced solid tumors. (TipRanks)

IND • New trial • Solid Tumor

CSPC PHARMA…has been approved by the National Medical Products Administration to commence clinical trials in China (iis.aastocks.com) - "The approved indication for this clinical trial is advanced solid tumors."

New trial • Solid Tumor

SYS6051, a next-generation tissue factor-targeted antibody-drug conjugates for the treatment of TF-expressing malignancies (AACR 2025) - "Neither coagulation disorder nor skin rash was observed, superior to the historical toxicity data in NHP of the MTI-ADC. Taken together, SYS6051 has a wide therapeutic window because of promising efficacy, higher tolerability, stable PK profile, and could potentially provide benefits for the patients carrying TF positive malignancies."

ADC • Cervical Cancer • Oncology • Solid Tumor